Diagnostics Deal Trends 2025 – Part 1
Major players turn their M&A sights to platforms and
technologies with broad application to drive growth.

Diagnostics M&A activity in 2025 accelerated, surpassing
the prior year in both count and strategic significance. The
number of M&A and asset purchase deals exceeded 150
globally, strongly surpassing 2024’s volume, at ~50 deals.

Download the full report below.

H1 2025: Acceleration, Integration, and the Shift from Innovation to Infrastructure

H1 2025 saw sustained Dx deal activity, highlighting
sector resilience despite macroeconomic headwinds. We
identified a total deal volume of 174 across Q1 and Q2,
which was stable year-over-year (vs. 171 in H1 2024), but
deal composition signalled a strategic shift.

Over the past five years, the South Korean pharmaceutical and biotech sector has emerged as a hotbed for Licensing and Mergers and Acquisitions (M&A) activity, attracting interest from both domestic and international players. Its unprecedented growth is fuelled by a combination of innovation, government support, and market expansion strategies, alongside the strategic need to access advanced technologies and global markets. This white paper provides an in-depth analysis of the key trends, drivers, and notable transactions that have shaped this dynamic sector, and highlights how international companies can benefit from this thriving market.